Anti-NY-ESO-1 monoclonal antibody - CT AtlanticAlternative Names: CTA-001
Latest Information Update: 05 Jul 2016
At a glance
- Originator CT Atlantic AG
- Developer CT Atlantic AG; Ludwig Institute for Cancer Research; University of Zurich
- Class Antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jul 2016 Preclinical trials in Cancer in Switzerland (unspecified route)